It is important to note that anti-IL-17 treatment in psoriasis, which is a prominent risk factor for cardiovascular diseases [51,52], strongly reduced the psoriasis burden; however, the effect on atherosclerosis was rather mild [53]. Here, IL17A is linked to psoriasis.